Abstract: The present invention provides a method for recovering a device (D). The method comprises the steps of acquiring a recovery code with the device (D) to be recovered, matching an inherence factor of a user recovering the device (D) with an inherence factor of a user which is assigned to the device, and allowing a recovery of the device (D) if the inherence factor of the user recovering the device and the inherence factor of the user which is assigned to the device sufficiently matches. A further method is provided which comprises the steps of connecting the device (D) to be recovered to a cloud storage in which a backup of the device is stored, requesting a knowledge factor from the user recovering the device (D), allowing a recovery of the device (D) if the possession factor is correctly inputted into the device (D) to be recovered. Further an App is provided which can be stored on a device, which App contains instructions for carrying out the method.

Abstract: Disclosed is a method of treating a subject suffering from a cancer, comprising administering to the subject a combination of agents comprising: (a) Compound I: or a pharmaceutically acceptable salt thereof; and (b) one or more inhibitors of the androgen receptor signaling pathway; or (c) one or more PARP inhibitors; wherein the amount of the combination of agents is therapeutically effective in the treatment.

Abstract: A transition barrier for transitioning from a permanent median barrier to a temporary median barrier, the transition barrier having: a) a first end; the first end being connectable to the permanent median barrier by a permanent median barrier connector; b) a second end; the second end being connectable to the temporary median barrier by a temporary median barrier connector; c) a transition section defining a transition wall of a predetermined length between the first end and the second end; the transition wall having a top, bottom, front and a back; d) at least one barrier brace proximate the transition wall, for supporting said transition wall; and e) at least one spacer, proximate the back of the transition wall for contact with a surface of the permanent concrete barrier.

Abstract: Provided herein are heterocyclic compounds of Formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses, methods for their preparation, intermediate compounds, pharmaceutical compositions containing such a compound, and their therapeutic uses.

Abstract: A method comprises receiving, at a first entity, an insurance claim for a health care service provided to a person by a provider; providing the claim from the first entity to an editing service, wherein the editing service is configured to edit the claim in accordance with information associated with a second entity and generate an edited claim, wherein the second entity is different than the first entity; receiving, at the first entity, the edited claim from the editing service; and determining, at the first entity, a payment to be made to the provider based on the edited claim. This method may be performed during the claim's adjudication cycle in realtime, not retrospectively.

Abstract: Forms of 4-(6-(3,5-dimethylisoxazol-4-yl)-1-[(1S)-1-(2-pyridyl)ethyl]pyrrolo[3,2-b]pyridin-3-yl)benzoic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the forms of Compound I.

Abstract: Disclosed is a method of treating a subject suffering from a cancer, comprising administering to the subject a combination of agents comprising: (a) Compound I: or a pharmaceutically acceptable salt thereof; and (b) one or more inhibitors of the androgen receptor signaling pathway; or (c) one or more PARP inhibitors; wherein the amount of the combination of agents is therapeutically effective in the treatment.

Abstract: A support system for a sign mountable on at least two spaced apart foundation members, the system comprising: i) a base, preferably a length adjustable base, having a first end and a second end; ii) a vertical sign support having a first end and a second end wherein the second end is connected to the base; iii) a first foundation member bracket for connection to a first foundation member, the first foundation member bracket proximate the first end of the base; and iv) a second foundation member bracket for connection to a second foundation member distant the first foundation member, the second foundation member bracket proximate the second end of the base.

Abstract: Provided herein are heterocyclic compounds of Formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses, methods for their preparation, intermediate compounds, pharmaceutical compositions containing such a compound, and their therapeutic uses.

Abstract: A support system for a sign mountable on at least two spaced apart foundation members, the system comprising: i) a base, preferably a length adjustable base, having a first end and a second end; ii) a vertical sign support having a first end and a second end wherein the second end is connected to the base; iii) a first foundation member bracket for connection to a first foundation member, the first foundation member bracket proximate the first end of the base; and iv) a second foundation member bracket for connection to a second foundation member distant the first foundation member, the second foundation member bracket proximate the second end of the base.

Abstract: Provided herein are heterocyclic compounds of Formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses, methods for their preparation, intermediate compounds, pharmaceutical compositions containing such a compound, and their therapeutic uses.

Abstract: Forms of 4-(6-(3,5-dimethylisoxazol-4-yl)-1-[(1S)-1-(2-pyridyl)ethyl]pyrrolo[3,2-b]pyridin-3-yl)benzoic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the forms of Compound I.

Abstract: Forms of 4-(6-(3,5-dimethylisoxazol-4-yl)-1-[(1S)-1-(2-pyridyl)ethyl]pyrrolo[3,2-b]pyridin-3-yl)benzoic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the forms of Compound I.

Abstract: Provided herein are heterocyclic compounds of Formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses, methods for their preparation, intermediate compounds, pharmaceutical compositions containing such a compound, and their therapeutic uses.

Abstract: A support system for a sign mountable on at least two spaced apart foundation members, the system comprising: i) a base, preferably a length adjustable base, having a first end and a second end; ii) a vertical sign support having a first end and a second end wherein the second end is connected to the base; iii) a first foundation member bracket for connection to a first foundation member, the first foundation member bracket proximate the first end of the base; and iv) a second foundation member bracket for connection to a second foundation member distant the first foundation member, the second foundation member bracket proximate the second end of the base.

Abstract: Provided herein are heterocyclic compounds of Formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses, methods for their preparation, intermediate compounds, pharmaceutical compositions containing such a compound, and their therapeutic uses.

Abstract: A transition barrier for transitioning from a permanent median barrier to a temporary median barrier, the transition barrier having: a) a first end; the first end being connectable to the permanent median barrier by a permanent median barrier connector; b) a second end; the second end being connectable to the temporary median barrier by a temporary median barrier connector; c) a transition section defining a transition wall of a predetermined length between the first end and the second end; the transition wall having a top, bottom, front and a back; d) at least one barrier brace proximate the transition wall, for supporting said transition wall; and e) at least one spacer, proximate the back of the transition wall for contact with a surface of the permanent concrete barrier.

Abstract: A support system for a sign mountable on at least two spaced apart foundation members, the system comprising: i) a base, preferably a length adjustable base, having a first end and a second end; ii) a vertical sign support having a first end and a second end wherein the second end is connected to the base; iii) a first foundation member bracket for connection to a first foundation member, the first foundation member bracket proximate the first end of the base; and iv) a second foundation member bracket for connection to a second foundation member distant the first foundation member, the second foundation member bracket proximate the second end of the base.

Abstract: Provided herein are heterocyclic compounds of Formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses, methods for their preparation, intermediate compounds, pharmaceutical compositions containing such a compound, and their therapeutic uses.

Abstract: Forms of 4-(6-(3,5-dimethylisoxazol-4-yl)-1-[(1S)-1-(2-pyridyl)ethyl]pyrrolo[3,2-b]pyridin-3-yl)benzoic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the forms of Compound I.